Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus

Cypryk, Katarzyna; Vilsbøll, Tina; Nadel, Iwona; Smyczyńska, Joanna; Holst, Jens J.; Lewiński, Andrzej

doi:10.1080/09513590601137004

Cited by 32 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We found that during the second trimester, fasting plasma active GLP1 levels correlated negatively with HOMA-R. In the past, Cypryk et al have shown a positive correlation of fasting total GLP1 with HOMA-R in a mixed population of 13 controls and 13 pregnancies with gestational diabetes mellitus (GDM) at the second trimester (27). This discrepancy might be due to the facts that in our study active GLP1 and not total GLP1 was measured, and active GLP1 was measured in a non-GDM population of women with normal pregnancies.…”

Section: Discussionmentioning

confidence: 80%

The role of maternal gut hormones in normal pregnancy: fasting plasma active glucagon-like peptide 1 level is a negative predictor of fetal abdomen circumference and maternal weight change

Valsamakis

Margeli

Vitoratos

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Maternal weight in pregnancy contributes to a glycemic environment that affects fetal growth. Gut peptides (glucagon-like peptide 1 (GLP1), glucose-dependent insulinotropic peptide (GIP), ghrelin, and peptide YY (PYY)) have been related to insulin sensitivity and secretion, weight control, and adipose tissue metabolism. This study aimed at examining the associations of gut hormones during pregnancy with maternal glucose homeostasis, maternal weight, and fetal growth. Methods: A total of 55 pregnant nonobese, nondiabetic Caucasian women were examined during the three trimesters of pregnancy, and anthropometric measurements, evaluation of fasting maternal plasma GLP1 (active), ghrelin (active), total PYY, total GIP, and a 75-g oral glucose tolerance test were done in them. Homeostasis model assessment (HOMA-R), insulin sensitivity index (ISI), and indices of insulin secretion were calculated. Fetal growth was estimated by ultrasound. Results: Fasting GLP1 increased significantly from the second to the third trimester (P!0.05). Fasting GLP1 correlated positively with high-density lipoprotein cholesterol (rZ0.52, PZ0.04). At the second trimester, fasting GLP1 levels correlated negatively with fetal abdomen circumference (rZK0.55, PZ0.034), birth weight (rZK0.50, PZ0.040), HOMA-R (rZK0.65, PZ0.001), insulin secretion, and triglycerides. At the first trimester, fasting ghrelin levels correlated negatively with HOMA-R and insulin secretion, and positively with ISI. In backward multiple regression analysis, the first trimester GLP1 levels were the best negative predictors of the second trimester fetal abdomen circumference (bZK0.96, PZ0.009). In longitudinal regression model, maternal fat and HOMA-R were the positive predictors of maternal weight change during pregnancy, and fasting GLP1 levels were the negative predictors of maternal weight change during pregnancy. Conclusions: During pregnancy, maternal GLP1 might be involved in mechanisms that compensate for the pregnancy-related increase in glycemia and insulin resistance, suggesting a role of this peptide in maternal metabolism and weight and fetal growth.

show abstract

Section: Discussionmentioning

confidence: 80%

The role of maternal gut hormones in normal pregnancy: fasting plasma active glucagon-like peptide 1 level is a negative predictor of fetal abdomen circumference and maternal weight change

Valsamakis

Margeli

Vitoratos

et al. 2010

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…The concentrations of these hormones were reported to be decreased or the stimulating effect of insulin secretion was reduced in type 2 diabetes, and a 50% reduction of these hormones in the sisters of the diabetes patients was reported [7-9]. The decreasing incretin effect of insulin secretion in type 2 diabetes was known, while the one of main pathogenesis pathway of type 2 diabetes, insulin secretion impairment is sometimes assumed to be an incretin disorder [8,10]. In terms of insulin resistance and insulin secretion disorders, in gestational diabetes, that is similar with type 2 diabetes, the likelihood of the failure of incretin effect has been reported.…”

Section: Introductionmentioning

confidence: 99%

“…In terms of insulin resistance and insulin secretion disorders, in gestational diabetes, that is similar with type 2 diabetes, the likelihood of the failure of incretin effect has been reported. However, using women with gestational diabetes as the primary subjects for a study on incretin hormone is considered to be controversial [10,11]. …”

Section: Introductionmentioning

confidence: 99%

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus

Cho

Lee

et al. 2011

Diabetes Metab J

View full text Add to dashboard Cite

BackgroundWe examined the change in the levels of incretin hormone and effects of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) on insulin secretion in women with previous gestational diabetes (pGDM).MethodsA 75-g oral glucose tolerance test (OGTT) was conducted on 34 women with pGDM. In addition, 11 women with normal glucose tolerance, matched for age, height and weight, were also tested. The insulin, GIP, GLP-1, and glucagon concentrations were measured, and their anthropometric and biochemical markers were also measured.ResultsAmong 34 women with pGDM, 18 had normal glucose tolerance, 13 had impaired glucose tolerance (IGT) and 1 had diabetes. No significant differences were found in GLP-1 concentration between the pGDM and control group. However, a significantly high level of glucagon was present in the pGDM group at 30 minutes into the OGTT. The GIP concentration was elevated at 30 minutes and 60 minutes in the pGDM group. With the exception of the 30-minute timepoint, women with IGT had significantly high blood glucose from 0 to 120 minutes. However, there was no significant difference in insulin or GLP-1 concentration. The GIP level was significantly high from 0 to 90 minutes in patients diagnosed with IGT.ConclusionGLP-1 secretion does not differ between pGDM patients and normal women. GIP was elevated, but that does not seem to induce in increase in insulin secretion. Therefore, we conclude that other factors such as heredity and environment play important roles in the development of type 2 diabetes.

show abstract

“…These GLP-1 upregulated, proliferation-related genes include: the prolactin receptor, which has been proposed to regulate islet mass expansion during pregnancy [14]; retinoblastoma binding protein-6 (RBBP6) is a multifunctional protein found ostensibly in all eukaryotes but not in bacteria, which is implicated in a diverse set of cellular functions including mRNA metabolism, regulation of the cell cycle, tumour igenesis and development. [15]; CSPG2, which regulates cell motility and growth under P53 activation [16]; S100A4 can act as a novel cardiac growth and survival factor and may have regenerative effects in injured myocardium [17]; CYLD, which acts as tumor suppressor gene [18]; SEMA3a, which inhibits the binding of the VEGF with 165-amino acids (VEGF-165) to np1 and was reported to inhibit angiogenesis [19].…”

Section: Discussionmentioning

confidence: 99%

The Global Transcriptional Response of Isolated Human Islets of Langerhans to Glucagon-Like Peptide-1 Receptor Agonist Liraglutide

Zhao

Tang

et al. 2012

ISRN Endocrinology

View full text Add to dashboard Cite

GLP-1 and its analog have been used in diabetes treatment; however, the direct alteration of gene expression profile in human islets induced by GLP-1 has not been reported. In present study, transcriptional gene expression in the liraglutide-treated human islets was analyzed with 12 human U133A chips including 23000 probe sets. The data compared between liraglutide and control groups showed a significant difference on glucose-induced insulin secretion, rather than viability. Microarray analysis identified 7000 genes expressed in human islets. Eighty genes were found to be modulated by liraglutide treatment. Furthermore, the products of these genes are proteins involved in binding capability, enzyme activity, transporter function, signal transduction, cell proliferation, apoptosis, and cell differentiation. Our data provides a set of information in the complex events, following the activation of the GLP-1 receptor in the islets of Langerhans.

show abstract

Normal secretion of the incretin hormones glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 during gestational diabetes mellitus

Abstract: An impaired secretion of GLP-1 and GIP does not seem to play a major role in the pathogenesis of GDM.

Cited by 32 publications

References 19 publications

The role of maternal gut hormones in normal pregnancy: fasting plasma active glucagon-like peptide 1 level is a negative predictor of fetal abdomen circumference and maternal weight change

The role of maternal gut hormones in normal pregnancy: fasting plasma active glucagon-like peptide 1 level is a negative predictor of fetal abdomen circumference and maternal weight change

Insulin Secretion and Incretin Hormone Concentration in Women with Previous Gestational Diabetes Mellitus

The Global Transcriptional Response of Isolated Human Islets of Langerhans to Glucagon-Like Peptide-1 Receptor Agonist Liraglutide

Contact Info

Product

Resources

About